EGFR and glioblastoma: The mechanistic and therapeutic insights in the kinase domain have not yet translated into clear therapeutic efficacy in glioblastoma, where it is still unclear how the specific EGFR ectodomain alterations—EGFRvIII in particular—can be properly targeted.